The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease
Open accessAbstract
OBJECTIVE: Assess Aβ deposition longitudinally and explore its relationship with cognition and disease progression. METHODS: Clinical follow-up was obtained 20 ± 3 months after [¹¹C]Pittsburgh compound B (PiB)-positron emission tomography in 206 subjects: 35 with dementia of the Alzheimer type (DAT), 65 with mild cognitive impairment (MCI), and 106 age-matched healthy controls (HCs). A second PiB scan was obtained at follow-up in 185 subjects and a third scan after 3 years in 57. RESULTS: At baseline, 97% of DAT, 69% of MCI, and 31% of HC subjects showed high PiB retention. At 20-month follow-up, small but significant increases in PiB standardized uptake value ratios were observed in the DAT and MCI groups, and in HCs with high PiB retention at baseline (5.7%, 2.1%, and 1.5%, respectively). Increases were associated with the number of apolipoprotein E ε4 alleles. There was a weak correlation between PiB increases and decline in cognition when all groups were combined. Progression to DAT occurred in 67% of MCI with high PiB versus 5% of those with low PiB, but 20% of the low PiB MCI subjects progressed to other dementias. Of the high PiB HCs, 16% developed MCI or DAT by 20 months and 25% by 3 years. One low PiB HC developed MCI. INTERPRETATION: Aβ deposition increases slowly from cognitive normality to moderate severity DAT. Extensive Aβ deposition precedes cognitive impairment, and is associated with ApoE genotype and a higher risk of cognitive decline in HCs and progression from MCI to DAT over 1 to 2 years. However, cognitive decline is only weakly related to change in Aβ burden, suggesting that downstream factors have a more direct effect on symptom progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and that progression of biomarker measures is also a continuous process that begins before symptoms [9–14]”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Numerous studies have shown that CU individuals with abnormal amyloid biomarkers have more rapid progression of atrophy, hypometabolism, and clinical/cognitive decline than individuals without biomarker evidence of Aβ deposition [13,33,80,93–99]”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The ε4 allele increased brain amyloid burden in a dose-dependent manner in normal elderly individuals and in mild cognitive impairment patients [93,94].”
From Plasma levels of apolipoprotein E, APOE genotype and risk of dementia and ischemic heart disease: A review (2016) · cites this paper as [94]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In a study characterizing sporadic AD, for instance, Villemagne et al. used Pittsburgh compound B (PiB) positron emission tomography (PET) to show that 31% of healthy control subjects had high PiB retention indicating Aß deposition and of these, 25% developed mild cognitive impairment or AD by 3 years (Villemagne et al., 2011).”
From Inhibiting USP16 rescues stem cell aging and memory in an Alzheimer’s model (2022) · cites this paper as Villemagne et al., 2011
In the citing paper
“Previous longitudinal studies have either failed to detect an early increase in regional Aβ deposition16 or identified a rather large early stage Aβ region including the posterior temporal, inferior parietal, posterior cingulate, precuneus, and occipital areas4.”
From Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity (2017) · cites this paper as [16]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Tzourio-Mazoyer, N., Landeau, B., Papathanassiou, D., Crivello, F., Etard, O., Delcroix, N., Mazoyer, B., & Joliot, M. (2002) · NeuroImage · doi:10.1006/nimg.2001.0978 · Cited by 16,319
Mild Cognitive Impairment: Clinical Characterization and Outcome
Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., & Kokmen, E. (1999) · Archives of Neurology · doi:10.1001/archneur.56.3.303 · Cited by 8,980
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496
Self-citationVitamin E and Donepezil for the Treatment of Mild Cognitive Impairment
Petersen, R. C., Thomas, R. G., Grundman, M., Bennett, D., Doody, R., Ferris, S., Galasko, D., Jin, S., Kaye, J., Levey, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050151 · Cited by 1,844
Design and construction of a realistic digital brain phantom
Collins, D. L., Zijdenbos, A. P., Kollokian, V., Sled, J. G., Kabani, N. J., Holmes, C. J., & Evans, A. C. (1998) · IEEE Transactions on Medical Imaging · doi:10.1109/42.712135 · Cited by 1,825
Mitchell, A. J., & Shiri‐Feshki, M. (2009) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2008.01326.x · Cited by 1,659
Correlation Between Elevated Levels of Amyloid β-Peptide in the Brain and Cognitive Decline
Näslund, J. (2000) · JAMA · doi:10.1001/jama.283.12.1571 · Cited by 1,268
Imaging β-amyloid burden in aging and dementia
Rowe, C. C., Ng, S., Ackermann, U., Gong, S. J., Pike, K., Savage, G., Cowie, T. F., Dickinson, K. L., Maruff, P., Darby, D., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000261919.22630.ea · Cited by 1,104
Self-citationJack, C. R., Lowe, V. J., Weigand, S. D., Wiste, H. J., Senjem, M. L., Knopman, D. S., Shiung, M. M., Gunter, J. L., Boeve, B. F., Kemp, B. J., et al. (2009) · Brain · doi:10.1093/brain/awp062 · Cited by 1,099
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–200 of 836
Croot, K., Ballard, K. J., Leyton, C. E., & Hodges, J. R. (2012) · Journal of Speech Language and Hearing Research · doi:10.1044/1092-4388(2012/11-0323 · Cited by 156
Mormino, E. C., Brandel, M. G., Madison, C. M., Marks, S. M., Baker, S. L., & Jagust, W. J. (2011) · Cerebral Cortex · doi:10.1093/cercor/bhr255 · Cited by 151
The diagnostic value of FDG and amyloid PET in Alzheimer’s disease—A systematic review
Rice, L., & Bisdas, S. (2017) · European Journal of Radiology · doi:10.1016/j.ejrad.2017.07.014 · Cited by 156
Rabinovici, G. D., Knopman, D. S., Arbizu, J., Benzinger, T. L. S., Donohoe, K. J., Hansson, O., Herscovitch, P., Kuo, P. H., Lingler, J. H., Minoshima, S., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14338 · Cited by 163
Rainey-Smith, S. R., Mazzucchelli, G. N., Villemagne, V. L., Brown, B. M., Porter, T., Weinborn, M., Bucks, R. S., Milicic, L., Sohrabi, H. R., Taddei, K., et al. (2018) · Translational Psychiatry · doi:10.1038/s41398-018-0094-x · Cited by 144
Self-citationUshering in the study and treatment of preclinical Alzheimer disease
Langbaum, J. B. S., Fleisher, A., Chen, K., Ayutyanont, N., Lopera, F. J., Quiroz, Y. T., Caselli, R. J., Tariot, P. N., & Reiman, E. M. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.107 · Cited by 149
Shapes of the Trajectories of 5 Major Biomarkers of Alzheimer Disease
Jack, C. R., Vemuri, P., Wiste, H. J., Weigand, S. D., Lesnick, T. G., Lowe, V., Kantarci, K., Bernstein, M. A., Senjem, M. L., Gunter, J. L., et al. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.3405 · Cited by 145
Vlassenko, A. G., Mintun, M. A., Xiong, C., Sheline, Y. I., Goate, A., Benzinger, T. L. S., & Morris, J. C. (2011) · Annals of Neurology · doi:10.1002/ana.22608 · Cited by 148
Disease Tracking Markers for Alzheimer's Disease at the Prodromal (MCI) Stage
Drago, V., Babiloni, C., Bartrés‐Faz, D., Caroli, A., Bosch, B., Hensch, T., Didic, M., Klafki, H., Pievani, M., Jovicich, J., et al. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-0043 · Cited by 144
Dominantly Inherited Alzheimer Network: facilitating research and clinical trials
Moulder, K. L., Snider, B., Mills, S. L., Buckles, V. D., Santacruz, A. M., Bateman, R. J., & Morris, J. C. (2013) · Alzheimer's Research & Therapy · doi:10.1186/alzrt213 · Cited by 142
Cortical hypermetabolism in MCI subjects: a compensatory mechanism?
Ashraf, A., Fan, Z., Brooks, D. J., & Edison, P. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2919-z · Cited by 143
Amyloid tracers detect multiple binding sites in Alzheimer's disease brain tissue
Ni, R., Gillberg, P., Bergfors, A., Marutle, A., & Nordberg, A. K. (2013) · Brain · doi:10.1093/brain/awt142 · Cited by 135
Sabuncu, M. R., Buckner, R. L., Smoller, J. W., Lee, P. H., Fischl, B. R., & Sperling, R. A. (2011) · Cerebral Cortex · doi:10.1093/cercor/bhr348 · Cited by 134
Brain imaging in the study of Alzheimer's disease
Reiman, E. M., & Jagust, W. J. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2011.11.075 · Cited by 139
Effect of APOE ε4 genotype on amyloid-β and tau accumulation in Alzheimer’s disease
Baek, M. S., Cho, H., Lee, H. S., Lee, J., Ryu, Y. H., & Lyoo, C. H. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00710-6 · Cited by 137
Comparison of MR-less PiB SUVR quantification methods
Bourgeat, P., Villemagne, V. L., Doré, V., Brown, B. M., Macaulay, S. L., Martins, R. N., Masters, C. L., Ames, D. J., Ellis, K. A., Rowe, C. C., et al. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.04.033 · Cited by 131
Self-citationMartins, R. N., Villemagne, V., Sohrabi, H. R., Chatterjee, P., Shah, T. M., Verdile, G., Fraser, P., Taddei, K., Gupta, V. B., Rainey-Smith, S. R., et al. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-171145 · Cited by 129
Self-citationTrzepacz, P. T., Yu, P., Sun, J., Schuh, K. J., Case, M. G., Witte, M. M., Hochstetler, H. M., & Hake, A. M. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.06.018 · Cited by 131
Varied effects of age-related neuropathologies on the trajectory of late life cognitive decline
Boyle, P. A., Yang, J., Yu, L., Leurgans, S. E., Capuano, A. W., Schneider, J. A., Wilson, R. S., & Bennett, D. A. (2016) · Brain · doi:10.1093/brain/aww341 · Cited by 132
Cerebrovascular disease, beta-amyloid, and cognition in aging
Marchant, N. L., Reed, B. R., DeCarli, C. S., Madison, C. M., Weiner, M. W., Chui, H. C., & Jagust, W. J. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.10.001 · Cited by 127
Schmidt, M. E., Chiao, P., Klein, G., Matthews, D. C., Thurfjell, L., Cole, P. E., Margolin, R. A., Landau, S. M., Foster, N. L., Mason, N. S., et al. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.09.004 · Cited by 125
Rasmussen, K. L. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.10.037 · Cited by 125
BDNF Val66Met, Aβ amyloid, and cognitive decline in preclinical Alzheimer's disease
Lim, Y. Y., Villemagne, V. L., Laws, S. M., Ames, D., Pietrzak, R. H., Ellis, K. A., Harrington, K. D., Bourgeat, P., Salvado, O., Darby, D., et al. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.05.006 · Cited by 124
Self-citationLeuzy, A., Janelidze, S., Mattsson-Carlgren, N., Palmqvist, S., Jacobs, D., Cicognola, C., Stomrud, E., Vanmechelen, E., Dage, J. L., & Hansson, O. (2021) · Neurology · doi:10.1212/wnl.0000000000012727 · Cited by 128
Basal forebrain atrophy correlates with amyloid β burden in Alzheimer's disease
Kerbler, G. M., Fripp, J., Rowe, C. C., Villemagne, V. L., Salvado, O., Rose, S., & Coulson, E. J. (2014) · NeuroImage Clinical · doi:10.1016/j.nicl.2014.11.015 · Cited by 128
Self-citationTau imaging in neurodegenerative diseases
Dani, M., Brooks, D. J., & Edison, P. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-015-3231-2 · Cited by 128
Majdi, A., Sadigh‐Eteghad, S., Aghsan, S. R., Farajdokht, F., Vatandoust, S. M., Abbas-Abad, A. N., & Mahmoudi, J. (2020) · Reviews in the Neurosciences · doi:10.1515/revneuro-2019-0089 · Cited by 130
Sperling, R. A., Johnson, K. A., Doraiswamy, P. M., Reiman, E. M., Fleisher, A., Sabbagh, M. N., Sadowsky, C., Carpenter, A. P., Davis, M. D., Lu, M., et al. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.06.014 · Cited by 127
The aging brain and cognition: contribution of vascular injury and aβ to mild cognitive dysfunction
Marchant, N. L., Reed, B. R., Sanossian, N., Madison, C. M., Kriger, S., Dhada, R., Mack, W. J., DeCarli, C., Weiner, M. W., Mungas, D. M., et al. (2013) · JAMA Neurology · doi:10.1001/2013.jamaneurol.405 · Cited by 106
Small-molecule PET Tracers for Imaging Proteinopathies
Mathis, C. A., Lopresti, B. J., Ikonomović, M. D., & Klunk, W. E. (2017) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2017.06.003 · Cited by 124
Self-citationCerebrospinal Fluid Biomarkers of Neurovascular Dysfunction in Mild Dementia and Alzheimer'S Disease
Sweeney, M. D., Sagare, A. P., & Zlokovic, B. V. (2015) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2015.76 · Cited by 122
Zhang, S., Han, D., Tan, X., Feng, J., Guo, Y., & Ding, Y. (2012) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2011.02845.x · Cited by 123
Blood-Based Proteomic Biomarkers of Alzheimer’s Disease Pathology
Baird, A. L., Westwood, S., & Lovestone, S. (2015) · Frontiers in Neurology · doi:10.3389/fneur.2015.00236 · Cited by 122
APP/Aβ structural diversity and Alzheimer's disease pathogenesis
Roher, A. E., Kokjohn, T. A., Clarke, S. G., Sierks, M. R., Maarouf, C. L., Serrano, G. E., Sabbagh, M., & Beach, T. G. (2017) · Neurochemistry International · doi:10.1016/j.neuint.2017.08.007 · Cited by 126
In vivo characterization of the early states of the amyloid-beta network
Sepulcre, J., Sabuncu, M. R., Becker, A., Sperling, R., & Johnson, K. A. (2013) · Brain · doi:10.1093/brain/awt146 · Cited by 117
Hippocampal activation is associated with longitudinal amyloid accumulation and cognitive decline
Leal, S. L., Landau, S. M., Bell, R. K., & Jagust, W. J. (2017) · eLife · doi:10.7554/elife.22978 · Cited by 117
Yokoi, T., Watanabe, H., Yamaguchi, H., Bagarinao, E., Masuda, M., Imai, K., Ogura, A., Ohdake, R., Kawabata, K., Hara, K., et al. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00304 · Cited by 116
Cerebral microhemorrhage and brain β-amyloid in aging and Alzheimer disease
Yates, P. A., Sirisriro, R., Villemagne, V. L., Farquharson, S., Masters, C. L., Rowe, C. C., & For the AIBL Research Group (2011) · Neurology · doi:10.1212/wnl.0b013e318221ad36 · Cited by 130
Self-citationRegional brain hypometabolism is unrelated to regional amyloid plaque burden
Altmann, A., Ng, B., Landau, S. M., Jagust, W. J., & Greicius, M. D. (2015) · Brain · doi:10.1093/brain/awv278 · Cited by 117
Teipel, S. J., Grothe, M. J., Zhou, J. H., Sepulcre, J., Dyrba, M., Sorg, C., & Babiloni, C. (2016) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617715000995 · Cited by 117
Aβ-amyloid and Tau Imaging in Dementia
Villemagne, V. L., Doré, V., Bourgeat, P., Burnham, S. C., Laws, S., Salvado, O., Masters, C. L., & Rowe, C. C. (2017) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2016.09.006 · Cited by 110
Self-citationDifferential effect of APOE genotype on amyloid load and glucose metabolism in AD dementia
Ossenkoppele, R., van der Flier, W. M., Zwan, M. D., Adriaanse, S. F., Boellaard, R., Windhorst, A. D., Barkhof, F., Lammertsma, A. A., Scheltens, P., & van Berckel, B. N. M. (2013) · Neurology · doi:10.1212/wnl.0b013e31827f0889 · Cited by 112
Lundqvist, R., Lilja, J., Thomas, B. A., Lötjönen, J. M. P., Villemagne, V. L., Rowe, C. C., & Thurfjell, L. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.115006 · Cited by 110
Self-citationLim, Y. Y., Villemagne, V. L., Laws, S. M., Ames, D., Pietrzak, R. H., Ellis, K. A., Harrington, K., Bourgeat, P., Bush, A. I., Martins, R. N., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0086498 · Cited by 110
Self-citationPhonologic errors as a clinical marker of the logopenic variant of PPA
Leyton, C. E., Ballard, K. J., Piguet, O., & Hodges, J. R. (2014) · Neurology · doi:10.1212/wnl.0000000000000387 · Cited by 118
In vivo visualization of tau deposits in corticobasal syndrome by 18 F-THK5351 PET
Kikuchi, A., Okamura, N., Hasegawa, T., Harada, R., Watanuki, S., Funaki, Y., Hiraoka, K., Baba, T., Sugeno, N., Oshima, R., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000003375 · Cited by 113
Lim, Y. Y., Jaeger, J., Harrington, K., Ashwood, T., Ellis, K. A., Stöffler, A., Szoeke, C. E. I., Lachovitzki, R., Martins, R. N., Villemagne, V. L., et al. (2013) · Archives of Clinical Neuropsychology · doi:10.1093/arclin/act021 · Cited by 117
Self-citationCaselli, R. J., & Reiman, E. M. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-129026 · Cited by 111
Scoring by nonlocal image patch estimator for early detection of Alzheimer's disease
Pierrick Coupé, A., Eskildsen, S. F., Manjón, J. V., Fonov, V., Pruessner, J. C., Michèle Allard, A., & Collins, D. L. (2012) · NeuroImage Clinical · doi:10.1016/j.nicl.2012.10.002 · Cited by 109
Insel, P. S., Mormino, E. C., Aisen, P. S. S., Thompson, W. K., & Donohue, M. (2020) · Brain Communications · doi:10.1093/braincomms/fcaa007 · Cited by 112
Alzheimer’s Disease: Biomarkers in the Genome, Blood, and Cerebrospinal Fluid
Huynh, R. A., & Mohan, C. (2017) · Frontiers in Neurology · doi:10.3389/fneur.2017.00102 · Cited by 112
Chiotis, K., Saint‐Aubert, L., Rodriguez‐Vieitez, E., Leuzy, A., Almkvist, O., Savitcheva, I., Jonasson, M., Lubberink, M., Wall, A., Antoni, G., et al. (2017) · Molecular Psychiatry · doi:10.1038/mp.2017.108 · Cited by 112
Stronger effect of amyloid load than APOE genotype on cognitive decline in healthy older adults
Lim, Y. Y., Ellis, K. A., Pietrzak, R. H., Ames, D. J., Darby, D., Harrington, K., Martins, R. N., Masters, C. L., Rowe, C. C., Savage, G. R., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e31826e9ae6 · Cited by 109
Self-citationAcosta‐Cabronero, J., & Nestor, P. J. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00266 · Cited by 109
Imaging and cerebrospinal fluid biomarkers in early preclinical alzheimer disease
Vlassenko, A. G., McCue, L., Jasielec, M. S., Su, Y., Gordon, B. A., Xiong, C., Holtzman, D. M., Benzinger, T. L. S., Morris, J. C., & Fagan, A. M. (2016) · Annals of Neurology · doi:10.1002/ana.24719 · Cited by 106
Fluid and PET biomarkers for amyloid pathology in Alzheimer's disease
Cohen, A. D., Landau, S. M., Snitz, B. E., Klunk, W. E., Blennow, K., & Zetterberg, H. (2018) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2018.12.004 · Cited by 112
Self-citationBallard, K. J., Savage, S., Leyton, C. E., Vogel, A. P., Hornberger, M., & Hodges, J. R. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089864 · Cited by 105
APOE-related biomarker profiles in non-pathological aging and early phases of Alzheimer's disease
Reinvang, I., Espeseth, T., & Westlye, L. T. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.05.006 · Cited by 109
Vascular Hypothesis of Alzheimer Disease
Scheffer, S., Hermkens, D. M. A., van der Weerd, L., de Vries, H. E., & Daemen, M. J. A. P. (2021) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.120.311911 · Cited by 113
Ritchie, K. A., Carrière, I., Su, L., O'Brien, J. T., Lovestone, S., Wells, K., & Ritchie, C. W. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2017.02.008 · Cited by 108
O’Dell, R. S., Mecca, A. P., Chen, M.-K., Naganawa, M., Toyonaga, T., Lu, Y., Godek, T. A., Harris, J. E., Bartlett, H. H., Banks, E. R., et al. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00742-y · Cited by 107
Doré, V., Bullich, S., Rowe, C. C., Bourgeat, P., Konate, S., Sabri, O., Stephens, A. W., Barthel, H., Fripp, J., Masters, C. L., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.02.005 · Cited by 93
Self-citationSchütt, T., Helboe, L., Pedersen, L. Ø., Waldemar, G., Berendt, M., & Pedersen, J. T. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-151085 · Cited by 105
Plasma Aβ but Not Tau is Related to Brain PiB Retention in Early Alzheimer’s Disease
Tzen, K., Yang, S., Chen, T., Cheng, T.-W., Horng, H. E., Wen, H.-P., Huang, Y.-Y., Shiue, C., & Chiu, M. (2014) · ACS Chemical Neuroscience · doi:10.1021/cn500101j · Cited by 105
PET Neuroimaging of Alzheimer's Disease: Radiotracers and Their Utility in Clinical Research
Bao, W., Xie, F., Zuo, C., Guan, Y., & Huang, Y. H. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.624330 · Cited by 102
Is the Amyloid Hypothesis of Alzheimer's disease therapeutically relevant?
Teich, A. F., & Arancio, O. (2012) · Biochemical Journal · doi:10.1042/bj20120653 · Cited by 105
Altered whole-brain white matter networks in preclinical Alzheimer's disease
Fischer, F. U., Wolf, D., Scheurich, A., & Fellgiebel, A. (2015) · NeuroImage: Clinical · doi:10.1016/j.nicl.2015.06.007 · Cited by 105
Review of ‘the Potential Role of Arterial Stiffness in the Pathogenesis of Alzheimer’s Disease’
Hughes, T. M., Craft, S., & López, O. L. (2015) · Neurodegenerative Disease Management · doi:10.2217/nmt.14.53 · Cited by 105
Thal, D. R., Attems, J., & Ewers, M. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-141461 · Cited by 100
Hickey, J. L., Lim, S., Hayne, D. J., Paterson, B. M., White, J. M., Villemagne, V. L., Roselt, P. D., Binns, D., Cullinane, C. M., Jeffery, C. M., et al. (2013) · Journal of the American Chemical Society · doi:10.1021/ja4057807 · Cited by 98
Self-citationInfluence of Amyloid-β on Cognitive Decline After Stroke/Transient Ischemic Attack
Liu, W., Wong, A., Au, L. W. C., Yang, J., Wang, Z., Leung, E. Y. L., Chen, S., Ho, C. L., & Mok, V. (2015) · Stroke · doi:10.1161/strokeaha.115.010449 · Cited by 99
Using Pittsburgh Compound B for In Vivo PET Imaging of Fibrillar Amyloid-Beta
Cohen, A. D., Rabinovici, G. D., Mathis, C. A., Jagust, W. J., Klunk, W. E., & Ikonomović, M. D. (2012) · Advances in pharmacology · doi:10.1016/b978-0-12-394816-8.00002-7 · Cited by 103
Self-citationEffect of Complement CR1 on Brain Amyloid Burden During Aging and Its Modification by APOE Genotype
Thambisetty, M., An, Y., Nalls, M., Sojkova, J., Swaminathan, S., Zhou, Y., Singleton, A. B., Wong, D. F., Ferrucci, L., Saykin, A. J., et al. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.08.015 · Cited by 90
Synergistic interaction between amyloid and tau predicts the progression to dementia
Pascoal, T. A., Mathotaarachchi, S., Shin, M., Benedet, A. L., Mohades, S., Wang, S., Beaudry, T., Kang, M. S., Soucy, J., Labbe, A., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.11.005 · Cited by 101
Villemagne, V. L., Furumoto, S., Fodero‐Tavoletti, M. T., Harada, R., Mulligan, R. S., Kudo, Y., Masters, C. L., Yanai, K., Cc, R., & Okamura, N. (2012) · Future Neurology · doi:10.2217/fnl.12.34 · Cited by 101
Self-citationIn vivo tau imaging: Obstacles and progress
Villemagne, V. L., & Okamura, N. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.04.013 · Cited by 100
Self-citationAssociation of Brain Amyloid-β With Slow Gait in Elderly Individuals Without Dementia
Nadkarni, N. K., Perera, S., Snitz, B. E., Mathis, C. A., Price, J. C., Williamson, J. D., DeKosky, S. T., Klunk, W. E., & López, O. L. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.3474 · Cited by 94
Self-citationDetecting earlier stages of amyloid deposition using PET in cognitively normal elderly adults
Guo, T., Landau, S. M., Jagust, W. J., & Initiative, A. D. N. (2020) · Neurology · doi:10.1212/wnl.0000000000009216 · Cited by 92
Microstates as Disease and Progression Markers in Patients With Mild Cognitive Impairment
Musaeus, C. S., Nielsen, M. S., & Høgh, P. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00563 · Cited by 95
Predicting Symptom Onset in Sporadic Alzheimer Disease With Amyloid PET
Schindler, S. E., Li, Y., Buckles, V. D., Gordon, B. A., Benzinger, T. L. S., Wang, G., Coble, D., Klunk, W. E., Fagan, A. M., Holtzman, D. M., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000012775 · Cited by 89
Self-citationAbsolute 10-year risk of dementia by age, sex and APOE genotype: a population-based cohort study
Rasmussen, K. L., Tybjærg-Hansen, A., Nordestgaard, B. G., & Frikke-Schmidt, R. (2018) · Canadian Medical Association Journal · doi:10.1503/cmaj.180066 · Cited by 91
Individual estimates of age at detectable amyloid onset for risk factor assessment
Bilgel, M., An, Y., Zhou, Y., Wong, D. F., Prince, J. L., Ferrucci, L., & Resnick, S. M. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2015.08.166 · Cited by 94
3D mapping reveals network-specific amyloid progression and subcortical susceptibility in mice
Canter, R. G., Huang, W., Choi, H., Wang, J., Watson, L. A., Yao, C. G., Abdurrob, F., Bousleiman, S. M., Young, J. Z., Bennett, D. A., et al. (2019) · Communications Biology · doi:10.1038/s42003-019-0599-8 · Cited by 97
Kuszczyk, M. A., Sanchez, S., Pankiewicz, J., Kim, J., Duszczyk, M., Guridi, M., Asuni, A. A., Sullivan, P. M., Holtzman, D. M., & Sadowski, M. J. (2013) · The American Journal of Pathology · doi:10.1016/j.ajpath.2013.01.034 · Cited by 89
Wei, Z., Chen, X.-C., Song, Y., Pan, X.-D., Dai, X.-M., Zhang, J., Cui, X.-L., Wu, X.-L., & Zhu, Y.-G. (2016) · Chinese Medical Journal · doi:10.4103/0366-6999.186646 · Cited by 89
Timing of Biomarker Changes in Sporadic Alzheimer's Disease in Estimated Years from Symptom Onset
Li, Y., Yen, D., Hendrix, R. D., Gordon, B. A., Dlamini, S. L., Barthélemy, N. R., Aschenbrenner, A. J., Henson, R. L., Herries, E. M., Volluz, K., et al. (2024) · Annals of Neurology · doi:10.1002/ana.26891 · Cited by 90
International Work Group Criteria for the Diagnosis of Alzheimer Disease
Cummings, J. L., Dubois, B., Molinuevo, J. L., & Scheltens, P. (2013) · Medical Clinics of North America · doi:10.1016/j.mcna.2013.01.001 · Cited by 95
Amyloid-beta and depression in healthy older adults: A systematic review
Harrington, K., Lim, Y. Y., Gould, E., & Maruff, P. T. (2014) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867414557161 · Cited by 89
Clinical meaningfulness of subtle cognitive decline on longitudinal testing in preclinical AD
Papp, K. V., Buckley, R. F., Mormino, E. C., Maruff, P. T., Villemagne, V. L., Masters, C. L., Johnson, K. A., Rentz, D. M., Sperling, R. A., Amariglio, R. E., et al. (2019) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2019.09.074 · Cited by 85
Self-citationLombardi, V. C., Meirleir, K. L. D., Subramanian, K., Nourani, S. M., Dagda, R. K., Delaney, S. L., & Palotás, A. (2018) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2018.04.004 · Cited by 87
Recent Progress in Alzheimer’s Disease Research, Part 1: Pathology
Hane, F. T., Lee, B. Y., & Leonenko, Z. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-160882 · Cited by 92
Hou, T., Yang, H., Wang, W., Wu, Q., Tian, Y., & Jia, J. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-171110 · Cited by 85
Scam Awareness Related to Incident Alzheimer Dementia and Mild Cognitive Impairment
Boyle, P. A., Yu, L., Schneider, J. A., Wilson, R. S., & Bennett, D. A. (2019) · Annals of Internal Medicine · doi:10.7326/m18-2711 · Cited by 87
van der Kall, L. M., Truong, T. H., Burnham, S. C., Doré, V., Mulligan, R. S., Bozinovski, S., Lamb, F., Bourgeat, P., Fripp, J., Schultz, S. A., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000011222 · Cited by 84
Self-citationSoldan, A., Pettigrew, C. A., Li, S., Wang, M., Moghekar, A., Selnes, O. A., Albert, M., & O’Brien, R. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.06.017 · Cited by 89
Modes of Aβ toxicity in Alzheimer’s disease
Götz, J., Eckert, A., Matamales, M., Ittner, L. M., & Liu, X. (2011) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-011-0750-2 · Cited by 87
Imaging Brain Effects of APOE4 in Cognitively Normal Individuals Across the Lifespan
Fouquet, M., Besson, F. L., Gonneaud, J., Joie, R. L., & Chételat, G. (2014) · Neuropsychology Review · doi:10.1007/s11065-014-9263-8 · Cited by 89
Self-citationA Systematic Review of Longitudinal Studies Which Measure Alzheimer’s Disease Biomarkers
Lawrence, E., Vegvari, C., Ower, A. K., Hadjichrysanthou, C., de Wolf, F., & Anderson, R. M. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170261 · Cited by 89
Longitudinal tau-PET uptake and atrophy in atypical Alzheimer's disease
Sintini, I., Martin, P. R., Graff‐Radford, J., Senjem, M. L., Schwarz, C. G., Machulda, M. M., Spychalla, A. J., Drubach, D. A., Knopman, D. S., Petersen, R. C., et al. (2019) · NeuroImage Clinical · doi:10.1016/j.nicl.2019.101823 · Cited by 87
Mind the gap: The mismatch between clinical and imaging metrics in ALS
Verstraete, E., Turner, M. R., Großkreutz, J., Filippi, M., Benatar, M. G., & meeting, O. B. O. T. A. O. T. 4. N. (2015) · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · doi:10.3109/21678421.2015.1051989 · Cited by 80
Metadata
- Authors
- Villemagne, V. L., Pike, K. E., Chételat, G., Ellis, K. A., Mulligan, R. S., Bourgeat, P., Ackermann, U., Jones, G., Szoeke, C., Salvado, O., Martins, R., O'Keefe, G., Mathis, C. A., Klunk, W. E., Ames, D., Masters, C. L., & Rowe, C. C.
- Affiliations
- Mental Health Research Institute (AU)
- Austin Health (AU)
- Commonwealth Scientific and Industrial Research Organisation (AU)
- Australian e-Health Research Centre (AU)
- Edith Cowan University (AU)
- University of Pittsburgh (US)
- National Ageing Research Institute (AU)
- The University of Melbourne (AU)
- Corresponding author
- Villemagne, Victor L.
- ORCID
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2011-01
- Volume
- 69
- Issue
- 1
- Pages
- 181-192
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- PMC
- PMC3045039
- OpenAlex
- W2051489981
- Cited by
- 833
- References
- 42
- Citations by year
- 2026: 28 · 2025: 32 · 2024: 26 · 2023: 51 · 2022: 42 · 2021: 44 · 2020: 57 · 2019: 60 · 2018: 57 · 2017: 57 · 2016: 60 · 2015: 61 · 2014: 68 · 2013: 86 · 2012: 71
- FWCI
- 57.02
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Annals of Neurology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- Edith Cowan University Research Online (Edith Cowan University) (submittedVersion)
- Funders
- National Institute on Aging (P01AG025204, RF1AG025516, P50AG005133, R37AG025516)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
- Keywords
- amyloid-beta deposition, Alzheimer's disease, mild cognitive impairment, Pittsburgh compound B PET, APOE ε4, cognitive decline, disease progression, aging
- MeSH terms
- Aged, Aging, Alzheimer Disease, Aniline Compounds, Brain, Cognition, Cognition Disorders, Female, Follow-Up Studies, Humans, Longitudinal Studies, Magnetic Resonance Imaging, Male, Neuropsychological Tests, Polymorphism, Genetic, Severity of Illness Index, Thiazoles, Amyloid beta-Peptides, Disease Progression, Positron-Emission Tomography, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
